HomeTrialNCT06878560
🔬NCT06878560Phase 1Phase 2RECRUITING

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

Study Summary

The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, 10 GE Xenokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment50 participants
Primary Completion
Lead SponsorUnited Therapeutics
Data Retrieved2026-04-11 04:30:42.432957+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.